That is essential, since the way a protein in the human body folds figures out if a pharmaceutical will have the ability to bind to that protein and work. In other words, we need to know how these proteins fold if we desire a drug to work. Historically, this has actually been an experimental process (diplomatic relations). Today, Alpha, Fold can anticipate protein folding with 92. 4% accuracy. That's going to make it a lot easier to develop drugs that do what they're designed to do. This was a breakthrough practically nobody saw. But it's going to have extensive ramifications for treating illness. I forecast that Alpha, Fold will be 98% accurate by the end of 2021.
And, naturally, there will be a lot of financial investment opportunities in this area, too. Moving topics It's going to be a great year for bitcoin. I'm bullish on it in 2021 (black sea). That said, I still think bitcoin will continue to be volatile. We're close to all-time highs. I wouldn't be surprised if it pulled back maybe significantly before going higher - jeff brown biotech picks. I've been covering bitcoin for a long time now. One of the first research reports I ever released was on bitcoin. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that preliminary suggestion, I entitled my report "What's the Big Deal With Bitcoin?" That reveals you where the discussion was at the time. We were mostly informing readers. However that's not the huge question anymore. Now we're seeing institutional money lastly take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, specific niche business. Mass, Mutual is a relied on 170-year-old organization. So consider that. In five years, we went from informing readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake.
Which's a huge factor I'm bullish on it this year. brownstone research. Regards, Jeff Brown, Editor, The Bleeding Edge I have a bonus offer forecast 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than 20 years. These business raised a total of $172 billion. That's an all-time high beating the previous yearly record by 43%. I anticipate 2021 will be another record year in IPOs. There are a lot of excellent personal companies on the edge of striking the general public markets And I've been dealing with a brand-new way for you to invest even before these companies go public.
This chance has actually been building over the last couple of years. I can't wait to inform you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Occasion to discover all the information. Go right here to reserve your spot free of charge.
Emma Walsh here, handling editor of the Journal. Routine Diary readers know that tech isn't our typical beat (tech stock). And when it pertains to tech investing, we leave it to the specialists. Fortunately, we have a number of such experts in our Rolodex. Our coworker Jeff Brown will be familiar to our long time readers. He is one of the most accomplished tech investing experts we know (jeff brown stock predictions). In fact, he had numerous triple-digit returns in his Brownstone Research study portfolios last year. Here's what Jeff believes the tech sector will bring us in 2021 Each year, I like to have a look at the huge picture and forecast what's simply around the corner.
That includes things like 5G networks, biotech, synthetic intelligence, and a lot more. These trends are experiencing exponential development and producing extraordinary opportunities for investors. I want to make sure all our readers are prepared for what's next. And with that in mind, let me draw the photo of what I see can be found in the next 12 months Our new 5G (fifth-generation) cordless networks are a topic I've been covering for years now. biotech stocks jeff brown. But regardless of what lots of readers might believe, this is a pattern that's simply getting going. Although the COVID-19 pandemic interrupted supply chains last year, an outstanding 250 million 5G-enabled devices were still offered.
And all of this ultimately resulted in Apple postponing the release of the 5G-enabled i, Phone 12 by 2 months (diplomatic relations). Losing 2 months of production and sales actually affects the number of 5G gadgets are sold in the calendar year. When you consider all of that, selling 250 million systems is exceptional. More significantly, the delays triggered by the pandemic produced a lots of bottled-up demand. And that demand is now going to be pushed into 2021. In truth, I predict that more than 500 million 5G gadgets will be shipped in 2021 - jeff brown prediction. And that's not my only 5G forecast When I've spoken about 5G in the past, I have actually described its three different stages.
In Stage Two, 5G gadgets go on sale. 5G phones and other products start to reach customers. And in Phase 3, 5G services begin to be offered (jeff brown prediction for 2021). That's when we start to see applications running on 5G networks. Consider things like enormous multiplayer video games over a mobile phone. That's not possible with 4G. It will be with 5G. And my second 5G prediction for 2021 is that we will begin Stage 3 by this summertime. This begins something of a virtuous cycle: Many people do not actually appreciate the technology. But they will care if there are amazing applications that can just be accessed with a 5G phone.
That causes more 5G apps being developed. In reality, 5G is going to open a suite of incredible applications: self-driving cars, the Internet of Things, robotic surgical treatment, and more. All of these technologies need 5G. The financial investment chances moving forward will be huge. Stepping away from 5G, the next crucial innovation I anticipate in 2021 is CRISPR hereditary editing. CRISPR represents "clustered frequently interspaced short palindromic repeat." It's a mouthful. However it is among the most amazing advancements in biotechnology. At a high level, CRISPR is a technology that can edit our hereditary makeup as if it were software.
The program can crash or not function properly. CRISPR uses a similar concept but with our genetic code. "Typos" in our genome can lead to illness. CRISPR can remedy these "typos." For several years, CRISPR was primarily a specific niche technology that wasn't well understood. And during that time, there were truly just three business running in this space. However things are changing. CRISPR is no longer just theoretical. We're seeing real outcomes. We're dealing with illness and seeing that this technology simply works. And as a result, a "second crop" of early-stage CRISPR companies is going public and delivering incredible returns. This whole industry is efficiently a greenfield chance.
There's room for numerous business to exist in this area. jeff brown biotech pick. And there will be more. That's my prediction for CRISPR in 2021. I anticipate that two or three more genetic editing companies will hold their IPOs. Sticking with biotechnology, we are seeing fantastic things taking place at the merging of biotech and synthetic intelligence (AI). Google's AI subsidiary, Deep, Mind, simply revealed at the end of 2020 that its most current Alpha, Fold software application can accurately forecast the folding of a protein based exclusively on its amino acid sequence with 92. 4% precision. That is essential because the way a protein in the body folds identifies if a pharmaceutical will be able to bind to that protein and work.
Historically, this has actually been an experimental process. However now, Alpha, Fold can anticipate protein folding with 92. 4% precision. That's going to make it a lot easier to produce drugs that do what they're developed to do. And here's my next prediction. I anticipate that Alpha, Fold will be 98% precise by the end of 2021. And we will see not just one however numerous drug therapies produced using this innovation. This was among those breakthroughs that nearly nobody observed. However it's going to have profound ramifications for treating disease. And, naturally, there will be plenty of financial investment opportunities in this area, too.
It's going to be a great year for bitcoin. I'm bullish on it in 2021. That stated, I still believe bitcoin will continue to be unstable. We're close to all-time highs. I wouldn't be surprised if it pulled back maybe significantly before going greater. I have actually been covering bitcoin for a long period of time now. One of the very first research study reports I ever published was on bitcoin - social media. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on financial investment for any person who followed my suggestion. But at the time of that initial recommendation, I titled my report, "What's the Big Deal With Bitcoin?" That reveals you where the discussion was at the time.
But nobody is asking that question anymore. Now, we're seeing institutional cash finally taking an interest in bitcoin. The big news was that Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, niche enterprise. jeff brown 1 biotech. Mass, Mutual is a 150-year-old organization. So believe about that. In 5 years, we went from educating readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. And that's a big factor why I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have one more reward forecast In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown deserves about $27. 5 million and claims the information depends on date since February 2021, however we could not individually validate this claim. Offered Jeff Brown's past, he likely has a substantial net worth, however we can't hammer down an exact figure at this moment. Brown is best understood for his sage-like ability to select winning innovation stocks. He spent more than 25 years investigating technology companies like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's substantial experience provides him an outstanding viewpoint on the market. He's always on the hunt for brand-new opportunities, and he shares much of his finest choices in the Near Future Report.
That's high praise, but it's not ridiculously reasoned. Brown has an excellent track record as a stock-picker, and he successfully predicted a few of the most significant financial events of the past 20 years. Although he doesn't appear to launch his picks to the public, the service's success is a direct indication of Brown's stock-picking expertise. No one on Wall Street gets it ideal every time, but Jeff Brown's accurate forecasts have earned him legions of dedicated fans. That says a lot about his ability. The Future Report is released by Brownstone Research, a prominent monetary research study publisher. Brownstone Research provides several research study services with a wide array of expertises - brownstone research.
The company is also associated with Bonner & Partners, another well-respected research study publisher - jeff brown stock picks 2021. On its website, Brownstone states its objective is to provide retail investors with professional-grade research: "For too long, the finest financial investment research study has not been readily available to individual investors. It has actually been usually scheduled for financial investment banks, hedge funds, private equity, and high-net-worth clients. genetic sequencer stock jeff brown. The mission of Brownstone Research is to make that type of exclusive research available to any investors seeking to get an edge in the markets. The objective is basic to deliver unique and successful financial investment research study discovered no place else." -Brownstone Research study website excerpt from the Jeff Brown is the creator of Brownstone Research, and he likewise acts as the company's Chief Financial investment Expert.
With Brown assisting the ship, Brownstone Research study is a powerhouse publisher with lots to offer its clients. After decades of constant success at the helm of top-tier companies like Tesla and Space, X, Elon Musk is a household name throughout many of America. If you understand even a bit about the market, you understand that he has a credibility as a King Midas of sorts. jeff brown 2021 stock predictions. Everything he touches relies on gold! Jeff is aware of Elon Musk's executive expertise, so he always has an eye out for the Silicon Valley rock star's next move. This time, Jeff has an early lead on Elon's next huge task.
In fact, Brown believes S.A.V. jeff brown. could be "the most significant pattern of the 2020s, and he's not alone. Take a look at these quotes from other popular S.A.V. bulls: Elon's next huge act will be weding 2 cutting-edge innovations: expert system and electrical cars. Musk hopes the mix will assist him develop the first fully-autonomous, self-driving automobiles ever. It's absolutely nothing except the automotive market's Holy Grail. As you know, electric lorries and self-driving vehicle stocks have actually been huge this year, however the Wall Street device has approved hype without much concrete outcome. In spite of an extreme boost in competition over the previous few years, Brown still thinks Musk has the very best opportunity of putting everything together.
tech could be the magic string that ties everything together. S.A.V. means Shared Autonomous Automobile, and it could be the future of transport. Basically, this technology would permit you to lease your vehicle as a self-governing, self-driving taxi when you're not using it. You merely get out of the automobile and press a button on an app that tells the cars and truck to "sign up with the fleet." Next thing you know, you're relaxing on your couch while your cars and truck shuttles ride-sharers around town. Best of all, you get to keep a substantial portion of the earnings. It sounds crazy, however it might be closed than you think.